HIGHLIGHTS
SUMMARY
Objective: To investigate possible sleep changes in patients with migraine treated with erenumab, using validated sleep questionnaires and home-PSG. The authors found a weak trend of improvement in daytime somnolence after 3 months of treatment, with stronger results after 12 months (median Epworth Sleepiness Scale (ESS) score from 6.0 to 4.0, p=0.015); a significant improvement in subjective sleep quality (median Pittsburgh Sleep Quality Index (PSQI) total score from 7 to 5; p=0.001) was also observed. Keyword migraine, PACAP, CGRP, erenumab, PSQI, sleep efficiency, polysomnography May 2022 | Volume . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.